nPhase closed a $30 million Series D funding round led by Viking Global Investors, the clinical research software company announced Monday, November 2. Its first equity raise since 2017 will support expansion of a platform that connects clinical-trial data from study startup through regulatory submission.
The Atlantic Beach, Florida, company said the money would help expand its enterprise clinical-data business, statistical computing tools, unified data management and AI-driven workflows. The financing announcement did not disclose a valuation, the size of Viking’s ownership stake or a timetable for spending the proceeds.
The funding follows the launch of nPhase.ai, which combines a Unified Data Management System with a Statistical Computing Environment. The company says that architecture brings data from research sites, laboratories, patients and digital health sensors into one governed system, rather than leaving study teams to reconcile disconnected records at the end of a trial.
nPhase says the platform standardizes and validates information as it arrives and can turn raw study data into submission-ready datasets and analysis packages in weeks instead of the four or more months those workflows can otherwise require. That speed comparison is the company’s claim; the financing release did not provide independent benchmarking or clinical results establishing it.
The company also describes AI agents that flag incoming data discrepancies and draft statistical programming. It says human experts retain decision authority. These are software capabilities intended to support research operations, not a substitute for a regulator’s review of evidence or approval of a therapy.
Chief Executive Scott Climes said the investment would support the next phase of nPhase’s AI-enabled workflows. Viking principal Levi Malik cited the company’s clinical-research background, understanding of regulatory requirements and plans for enterprise-scale AI as reasons for the investment. Those are the company’s and investor’s assessments of its prospects.
nPhase also operates REDCap Cloud, an electronic data-capture offering for small and midsize sponsors, nonprofit and academic researchers, medical-technology studies and real-world data programs. Its wider platform serves pharmaceutical sponsors and contract research organizations, according to the company.
The $30 million is the new funding round. The separate figure of more than $54 billion in the announcement describes capital managed by Viking across its public and private investments, not money raised by nPhase. Monday’s announcement is a financing milestone, not a trial readout, a therapy approval or a finding that an AI system has proved safe and effective in patient care.
JBizNews Desk | Atlantic Beach, Florida
© JBizNews.com. All rights reserved. Unauthorized reproduction or redistribution is strictly prohibited.
